We are monitoring the impact of COVID-19 on Middle East & Africa Immunotherapy Drugs Market Get in touch with us for detailed analysis Know More
Share on

Middle East & Africa Immunotherapy Drugs Market Research Report – Segmented By Drug Type, Application & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, Growth & Forecast | 2022 to 2027

Published: January, 2022
ID: 1097
Pages: 145

Middle East & Africa Immunotherapy Drugs Market Size & Growth (2022 to 2027):

The Size of the Immunotherapy Drugs Market in the Middle East & Africa is valued at USD 6.67 billion in 2022 and is estimated to reach USD 10.62 billion by 2027, with a CAGR of 9.74% during the forecast period 2022 to 2027.

MARKET DRIVERS

The proliferation of chronic diseases majorly drives the market in the region, monoclonal antibodies and biosimilars have been increasing, and the adoption of immunotherapy drugs has replaced conventional treatments. Also, rapid drug approval and a reduction in illness recurrence drive market growth. In addition, the market is growing at a fast pace due to the rise in cancer patients across the middle east African countries.

However, rising demand for monoclonal antibodies is estimated to uplift the market growth. On the other hand, the increasing advent of biologics is projected to propel market growth during the forecast period. Biologics are one of the fastest-growing therapeutic pharmaceuticals, significantly exceeding small-molecule drug manufacturing. In addition, increasing investment and funding activities by the various companies in the region are making collaborations to establish the number of research laboratories expected to uplift the market growth.

Furthermore, other factors such as diabetes, hypertension, depression, and obesity, and various lifestyle disorders and non-communicable diseases drive the market over the forecast period. However, the influence of COVID-19 on the immunotherapy pharmaceuticals industry has recently been favorable since several businesses are presently focusing on the development of COVID-19 immunotherapy-based medications or vaccines. Furthermore, according to a study published in the International Journal of General Medicine recently, mortality from many non-communicable diseases (NCDs) or chronic diseases continues to rise in the region, with a disproportionately more significant impact in low-middle income countries (LMIs), with chronic diseases accounting for significant deaths. Moreover, the demand for immunotherapy drugs is growing because the benefits provided are active or passive attack of drugs, high solubility bioavailability, and multifunctionality.

MARKET RESTRAINTS

During the projection period, however, the high price of immunotherapy medications and the high rate of attrition in the production process phase are projected to stymie the MEA immunotherapy medicines market.

Middle East & Africa Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories

By Drug Type: 

  • Monoclonal antibodies
  • Interferons
  • Interleukins
  • Vaccines
  • checkpoint inhibitors

By Application:

  • Blood Cancer
  • Cervical Cancer
  • Breast Cancer
  • Glioblastoma
  • Lung Cancer
  • Gastric Cancer
  • Prostate Cancer
  • Melanoma

By Country: 

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

REGIONAL ANALYSIS

The immunotherapy drugs market is expected to have the highest share during the forecast period. The market growth is attributed to the growing demand for novel technologies and the prevalence of cancer rates. However, lung cancer is projected to account for the largest share and dominate the coming years. The majority of immunotherapy medications are used to treat lung, breast, and prostate cancer.

Due to greater regulatory approvals and improved effectiveness, monoclonal antibodies became the most popular sector in this region. The developing countries such as Saudi Arabia, United Arab Emirates are introducing new molecules, the patients who have not responded to chemotherapy have benefited from the introduction of novel compounds.

Several new immunotherapeutic approaches, such as immunomodulators and CAR-T cell therapy, are being studied in the lab to see if they might improve cancer treatment. However, the government's favorable reimbursement policies and encouragement are influencing the market to grow in the United Arab Emirates.

Key Market Companies leading the Middle East & Africa Immunotherapy Drugs Market Profiled in the Report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Drug Type                             

                                5.1.1 Monoclonal Antibodies     

                                5.1.2 Interferons             

                                5.1.3 Interleukins            

                                5.1.4 Vaccines  

                                5.1.5 Checkpoint Inhibitors         

                5.2 By Application                           

                                5.2.1 Blood Cancer         

                                5.2.2 Cervical Cancer     

                                5.2.3 Breast Cancer        

                                5.2.4 Glioblastoma         

                                5.2.5 Lung Cancer           

                                5.2.6 Gastric Cancer       

                                5.2.7 Prostate Cancer    

                                5.2.8 Melanoma              

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 Middle-East                                

                6.3 Africa                            

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 Eli Lilly                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck                           

                9.3 Roche                           

                9.4 Amgen                         

                9.5 Novartis                       

                9.6 Celgene                       

                9.7 AstraZeneca               

                9.8 Bristol Myers Squibb                              

                9.9 GlaxoSmithKline PLC                              

                9.10 Seattle Genetics                    

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Middle East & Africa Immunotherapy Drugs Market By Region, From 2022 - 2027 (USD Billion)
  2. Middle East & Africa Immunotherapy Drugs Market By Drug Type, From 2022 - 2027 (USD Billion)
  3. Middle East & Africa Monoclonal Antibodies Market By Region, From 2022 - 2027 (USD Billion)
  4. Middle East & Africa Interferons Market By Region, From 2022 - 2027 (USD Billion)
  5. Middle East & Africa Interleukins Market By Region, From 2022 - 2027 (USD Billion)
  6. Middle East & Africa Vaccines Market By Region, From 2022 - 2027 (USD Billion)
  7. Middle East & Africa Checkpoint Inhibitors Market By Region, From 2022 - 2027 (USD Billion)
  8. Middle East & Africa Immunotherapy Drugs Market By Application, From 2022 - 2027 (USD Billion)
  9. Middle East & Africa Blood Cancer Market By Region, From 2022 - 2027 (USD Billion)
  10. Middle East & Africa Cervical Cancer Market By Region, From 2022 - 2027 (USD Billion)
  11. Middle East & Africa Breast Cancer Market By Region, From 2022 - 2027 (USD Billion)
  12. Middle East & Africa Glioblastoma Market By Region, From 2022 - 2027 (USD Billion)
  13. Middle East & Africa Lung Cancer Market By Region, From 2022 - 2027 (USD Billion)
  14. Middle East & Africa Gastric Cancer Market By Region, From 2022 - 2027 (USD Billion)
  15. Middle East & Africa Prostate Cancer Market By Region, From 2022 - 2027 (USD Billion)
  16. Middle East & Africa Melanoma Market By Region, From 2022 - 2027 (USD Billion)
  17. Middle East Immunotherapy Drugs Market By Drug Type, From 2022 - 2027 (USD Billion)
  18. Middle East Immunotherapy Drugs Market By Application, From 2022 - 2027 (USD Billion)
  19. Africa Immunotherapy Drugs Market By Drug Type, From 2022 - 2027 (USD Billion)
  20. Africa Immunotherapy Drugs Market By Application, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

2875


pdf excel
$

3220


pdf excel powerbi
$

4600


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2875

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample